These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 10469432)

  • 1. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
    Weiss B; Bollag G; Shannon K
    Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21.
    Hattori S; Maekawa M; Nakamura S
    Oncogene; 1992 Mar; 7(3):481-5. PubMed ID: 1549362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
    Bollag G; Clapp DW; Shih S; Adler F; Zhang YY; Thompson P; Lange BJ; Freedman MH; McCormick F; Jacks T; Shannon K
    Nat Genet; 1996 Feb; 12(2):144-8. PubMed ID: 8563751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular genetics of neurofibromatosis type 1].
    Suzuki H; Takahashi K; Shibahara S
    Nihon Rinsho; 1993 Sep; 51(9):2457-61. PubMed ID: 8411728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.
    Basu TN; Gutmann DH; Fletcher JA; Glover TW; Collins FS; Downward J
    Nature; 1992 Apr; 356(6371):713-5. PubMed ID: 1570015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of rasGAP and neurofibromatosis gene product activities.
    Bollag G; McCormick F
    Nature; 1991 Jun; 351(6327):576-9. PubMed ID: 1904555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ras effector loop mutations that dissociate p120GAP and neurofibromin interactions.
    Stang S; Bottorff D; Stone JC
    Mol Carcinog; 1996 Jan; 15(1):64-9. PubMed ID: 8561868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention.
    Parada LF; Kwon CH; Zhu Y
    Cold Spring Harb Symp Quant Biol; 2005; 70():173-6. PubMed ID: 16869751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the neurofibromatosis type 1 (NF1) GAP-related domain by site-directed mutagenesis.
    Gutmann DH; Boguski M; Marchuk D; Wigler M; Collins FS; Ballester R
    Oncogene; 1993 Mar; 8(3):761-9. PubMed ID: 8437860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors.
    Guha A; Lau N; Huvar I; Gutmann D; Provias J; Pawson T; Boss G
    Oncogene; 1996 Feb; 12(3):507-13. PubMed ID: 8637706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coupling of ras p21 signalling and GTP hydrolysis by GTPase activating proteins.
    McCormick F
    Philos Trans R Soc Lond B Biol Sci; 1992 Apr; 336(1276):43-7; discussion 47-8. PubMed ID: 1351295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [NF1 (neurofibromatosis type 1)].
    Maruta H; Nur-e-Kamal
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1422-6. PubMed ID: 9309135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Ras effector mutant interactions with the NF1-GAP related domain.
    Marshall MS; Hettich LA
    Oncogene; 1993 Feb; 8(2):425-31. PubMed ID: 8426748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulus-evoked release of neuropeptides is enhanced in sensory neurons from mice with a heterozygous mutation of the Nf1 gene.
    Hingtgen CM; Roy SL; Clapp DW
    Neuroscience; 2006; 137(2):637-45. PubMed ID: 16298082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes.
    Dasgupta B; Li W; Perry A; Gutmann DH
    Cancer Res; 2005 Jan; 65(1):236-45. PubMed ID: 15665300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
    Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
    Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the interaction of p21c-Ha-ras-GMP-PNP with full-length neurofibromin and GTPase-activating protein.
    DiBattiste D; Golubic M; Stacey D; Wolfman A
    Oncogene; 1993 Mar; 8(3):637-43. PubMed ID: 8437847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofibromatosis type 1 gene mutations in neuroblastoma.
    The I; Murthy AE; Hannigan GE; Jacoby LB; Menon AG; Gusella JF; Bernards A
    Nat Genet; 1993 Jan; 3(1):62-6. PubMed ID: 8490657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.